|
|
Hokkaido University Collection of Scholarly and Academic Papers >
Graduate School of Medicine / Faculty of Medicine >
Peer-reviewed Journal Articles, etc >
Effects of 50 mg vildagliptin twice daily vs. 50 mg sitagliptin once daily on blood glucose fluctuations evaluated by long-term self-monitoring of blood glucose
| Title: | Effects of 50 mg vildagliptin twice daily vs. 50 mg sitagliptin once daily on blood glucose fluctuations evaluated by long-term self-monitoring of blood glucose |
| Authors: | Nomoto, Hiroshi Browse this author | | Kimachi, Kimihiko Browse this author | | Miyoshi, Hideaki Browse this author →KAKEN DB | | Kameda, Hiraku Browse this author | | Cho, Kyu Yong Browse this author | | Nakamura, Akinobu Browse this author →KAKEN DB | | Nagai, So Browse this author →KAKEN DB | | Kondo, Takuma Browse this author | | Atsumi, Tatsuya Browse this author →KAKEN DB |
| Keywords: | Blood glucose fluctuation | | DPP-4 inhibitors | | Type 2 diabetes mellitus |
| Issue Date: | Apr-2017 |
| Publisher: | The Japan Endocrine Society |
| Journal Title: | Endocrine Journal |
| Volume: | 64 |
| Issue: | 4 |
| Start Page: | 417 |
| End Page: | 424 |
| Publisher DOI: | 10.1507/endocrj.EJ16-0546 |
| PMID: | 28260702 |
| Abstract: | To date, several clinical trials have compared differences in glucose fluctuation observed with dipeptidyl peptidase-4 inhibitor treatment in patients with type 2 diabetes mellitus. However, most patients were assessed for limited periods or during hospitalization. The aim of the present study was to evaluate the effects of switching from sitagliptin to vildagliptin, or vice versa, on 12-week glucose fluctuations using self-monitoring of blood glucose in the standard care setting. We conducted a multicenter, prospective, open-label controlled trial in Japanese patients with type 2 diabetes. Thirty-two patients were treated with vildagliptin (50 mg) twice daily or sitagliptin (50 mg) once daily and were allocated to one of two groups: vildagliptin treatment for 12 weeks before switching to sitagliptin for 12 weeks, or vice versa. Daily profiles of blood glucose were assessed several times during each treatment period, and the mean amplitude of glycemic excursions and M-value were calculated. Metabolic biomarkers such as hemoglobin A1c (HbA1c), glycated albumin, and 1,5-anhydroglucitol were also assessed. With vildagliptin treatment, mean amplitude of glycemic excursions was significantly improved compared with sitagliptin treatment (57.9 ± 22.2 vs. 68.9 ± 33.0 mg/dL; p=0.0045). M-value (p=0.019) and mean blood glucose (p=0.0021) were also lower with vildagliptin, as were HbA1c, glycated albumin, and 1,5-anhydroglucitol. There were no significant differences in other metabolic parameters evaluated. Reduction of daily blood glucose profile fluctuations by vildagliptin was superior to that of sitagliptin in Japanese patients with type 2 diabetes. |
| Type: | article |
| URI: | http://hdl.handle.net/2115/68414 |
| Appears in Collections: | 医学院・医学研究院 (Graduate School of Medicine / Faculty of Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
|
Submitter: 三好 秀明
|
